> Juvenescence told Longevity.Technology it has delayed its planned IPO from this year to the second half of 2020. The company now plans to raise a series C round before listing on a U.S. stock exchange. Article
> The FDA accepted DBV Technologies’ application for approval of Viaskin Peanut. The acceptance comes almost 10 months after DBV withdrew its original filing. Release
> Bavarian Nordic began a phase 1 trial of a vaccine candidate against the equine encephalitis virus. Topline data from the 45-subject study are due next year. Statement
> The FDA granted fast-track designation to Mereo BioPharma’s navicixizumab in ovarian cancer. The drug is in phase 1b. Release
> Galderma said a phase 2 trial “successfully demonstrated the safety and efficacy” of its liquid botulinum toxin type A formulation. A phase 3 trial is due to start soon. Statement
> Motif Bio revealed it will take “several years” and “tens of millions of dollars” to address the FDA’s request for additional data on its antibiotic iclaprim. Motif wants to find a partner for the trial. Release